品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

Selleck Chemicals/Fedratinib (TG101348)/S2736

价格
¥11400.00
货号:S2736
浏览量:127
品牌:Selleck Chemicals
服务
全国联保
正品保证
正规发票
签订合同
商品描述
DescriptionFedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Targets
JAK2 [1](Cell-free assay)JAK2 (V617F) [1](Cell-free assay)FLT3 [1](Cell-free assay)RET [1](Cell-free assay)
3 nM3 nM15 nM48 nM
In vitro

TG-101348 also significantly inhibits JAK2 V617F, Flt3, and Ret with IC50 of 3 nM, 15 nM, and 48 nM, respectively. TG101348 has an IC50 ~300-fold higher for the closely related JAK3 and is a less potent inhibitor of the JAK1 and TYK2 family members. TG101348 inhibits proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with IC50 of 305 nM and 270 nM, respectively. TG-101348 also inhibits proliferation of parental Ba/F3 cells to a comparable level, with IC50 of ~420 nM. TG101348 treatment reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. TG101348 does not show proapoptotic activity in control normal human dermal fibroblasts at concentrations up to 10 μM, and the antiproliferative IC50 against fibroblasts is >5 μM. [1] TG101348 treatment decreases GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibits STAT5 as well as GATA S310 phosphorylation. [2] TG101348 inhibits the proliferation of HMC-1.1 (KITV560G) cells, with somewhat lower potency than HMC-1.2 (KITD816V, KITV560G) cells, with IC50 of 740 nM and 407 nM, respectively. [3]

Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H1975MnzkRZBweHSxc3nzJGF{e2G7MniyNE42NTJizszNNVq1S44yOTJvNEigbC=>MWrEUXNQMYfpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNIraPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NUi2PVIyOCd-MkW4OlkzOTB:L3G+
H1650M4TR[GFxd3C2b4Ppd{BCe3OjeR?=NYPIbXdHOC53LUKg{txOMnqzNVIuPDhiaB?=MWDEUXNQMULpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNWTPXY9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
H1975MWDGeY5kfGmxbjDBd5NigQ>?NVHLenI4OC5{NT2xJO69VQ>?NFr4XVAzPCCqM1jxRmROW09?M2rWTYlvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiYYDvdJRwe2m|LYLlcIF1WRicILveIVqdiCEY3ytXGwtKEKlbD2yMEB{fXK4aYpckwhYEmDUB?=MUe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NITONnZHfW6ldHnvckBCe3OjeR?=MUGwMlI2NTFizszNNEfTR20zPCCqMUXEUXNQMVTpcohq[mm2czDlfJBzXO|aX;uJI9nKGGyb4D0c5Nqey2{ZXzheIVlKHC{b4TlbY4hSmOuLWjMMEBD[2xvMjygd5Vzfmm4aX6sJHhKSVB?M4LOVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3OE[5NlExLz5{NUi2PVIyODxxYU6=
H1975M{TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXuxJO69VQ>?NYHUPJlTPDhiaB?=MoHkSG1UVw>?NUjSTXZse2Wwc3n0bZpmeyClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjbZR6KG:oIHXycI91cW6rYh?=MVe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NYSxVHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrXVpo4OSEQvF2=MmnHOFghcA>?NXT1fW45TE2VTx?=Mn7Bd4Vve2m2aYrld{BkWyuczD0c{B1cGViY4n0c5RwgGmlaYT5JI9nKGW{bH;0bY5q[g>?NYPES5hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
CD4+TMmC5SpVv[3Srb36gRZN{[Xl?MXqwMlAyNTFizszNMoLpOFghcA>?MnTUSG1UVw>?NET4UFFzWS3Y3XzJJRpSCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJI9nKEqDS{KgZY5lKFOWQWSzxsA>Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{K1N|UoRjJ3NUeyOVM2RC:jPh?=
Caco-2NVnrPYxUTnWwY4Tpc44hSXO|YYm=M4fvbFAuOTJyIN88US=>NWrP[5lLPyCvaX6=MUDpcohq[mm2czD0bIlidWmwZTD1dJRic2Vid3n0bEBidiCLQ{WwxsBwiB{LkJCpOK2VQ>?M23bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3ME[zOlczLz5{NUC2N|Y4OjxxYU6=
Caco-2M2HWT2Z2dmO2aX;uJGF{e2G7Ml73NVAwPTBxMUCwJO69VQ>?NVPGUXV[OiCqMmjM[IVkemWjc3XzJJRpSCobIX4JI9nKFt|SG30bIlidWmwZTDhZ5Jwe3NidHjlJI1wdm:uYYnldkB4cXSqIFnDOVAhd2ZiNj61xsDPxE1?MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkO2O|IoRjJ3ME[zOlczRC:jPh?=
HEK293 MSRNILrTVJHfW6ldHnvckBCe3OjeR?=NV;GeVdEOC1zMDFOwG0>MYW3JI1qdg>?NWnp[GRrcW6qaXLpeJMhcFSKVGKyJJdqfGhiYX6gTWM2OMLib3[gNU4zyqEEtV2=MUS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4M{[3Nkc,OjVyNkO2O|I9N2F-
MedB-1MowSpVv[3Srb36gRZN{[Xl?NHn6NG8yNzJizszNM4m0NlI1KGh?NV7OdWV3GWlcnXhd4V{KFOWQWS2JJBpd3OyaH;yfYxifGmxbjDjc45kW62cnH0bY9vKGSncHXu[IVvfGy7MV28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5N{[2PEc,OjR7N{e2Olg9N2F-
U2940NULDT3g4TnWwY4Tpc44hSXO|YYm=MVGxM|Ih|ryPNFLDb40zPCCqMmPX[IVkemWjc3XzJHNVSVR4IIDoc5NxcG:{eXzheIlwdiClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K1106M162TmZ2dmO2aX;uJGF{e2G7M2DsblEwOiEQvF2=M3G0R|I1KGh?MX7k[YNzWG|ZYOgV3RCXDZicHjvd5Bpd3K7bHH0bY9vKGOxbnPlcpRz[XSrb36g[IVxW6mZX70cJk>MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K562NFr0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfoNE0yKM7:TR?=MY[3NkBpMVnpcohq[mm2czDLOVYzKGOnbHygdJJwdGmoZYLheIlwdiCjdDDobYdpKGOxbnPlcpRz[XSrb36=NY[2bWZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|U{ODhpPkK0O|c2OzB6PD;hQi=>
MDA-MB-468NXywSndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXOzJOK2VQ>?MX60PEBpM3T0OYVvcGGwY3XkJJNq[mOuNjDpcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJnDqA>?MXm8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ4MkixPEc,OjR4NkK4NVg9N2F-
MDA-MB-468MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIruZZExNTRizszNMWq0PEBpM4 OZJme3WudIOgd4lodmmoaXPhcpQhdG:|czDv[kB3cWGkaXzpeJkh[2:vcHHy[YQhfG9iUlmtRnBKKGGub37lM1roflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2Nk[yPFE5Lz5{NE[2NlgyQDxxYU6=
L428NH[zRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[wMVUh|ryPNEnTbHE1QCCqNYXST4xUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>M3fCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
KMH2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWCwMVUh|ryPMXq0PEBpMWXpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7MX:8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf3d40xNTVizszNNH2xeYY1QCCqNHvaXW9qdmirYnn0d{BkWyuIHfyc5d1cCC|aXfubYZq[2GwdHz5NETrSmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDhNE02KM7:TR?=NGIdos1QCCqNVSwVpJUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>NVPJfWNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXYNE02KM7:TR?=M4D1[FQ5KGh?MVzpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7NH3xeYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PNF7n[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUSwMVUh|ryPNGH2N2c1QCCqM2rE[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=Mn QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
L428MYXBdI9xfG:|aYOgRZN{[Xl?NXH5cGZbOC9yLk[yOU8yNjJ3IN88US=>NIPMeY81QCCqMVpcoR2[2W|IITo[UBieG:ydH;zbZPDqA>?NYezNXVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
KMH2NUHTe3l7SXCxcITvd4l{KEG|c3H5M1r3TlAwOC54MkWvNU4zPSEQvF2=MmnQOFghcA>?Ml3PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M4nFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L1236NXzIfGJJSXCxcITvd4l{KEG|c3H5NEXNc|kxNzBwNkK1M|EvOjVizszNMkKwOFghcA>?M1;DVIlvHWlZYOgeIhmKGGyb4D0c5Nqe8LiNHSwVZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1NFfYW4RCeG:ydH;zbZMhSXO|YYm=MV[wM|AvPjJ3L{GuNlUh|ryPNVnYSW5ZPDhiaB?=Mn7PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M333SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
HDLM2Mkf3RZBweHSxc3nzJGF{e2G7MlzvNE8xNjZ{NT:xMlI2KM7:TR?=NHjzNWc1QCCqMnnPbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M1jnXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
K1106PMoKwRZBweHSxc3nzJGF{e2G7MWmwM|AvPjJ3L{GuNlUh|ryPM2HDZ|Q5KGh?NWX5[YhIcW6mdXPld{B1cGViYYDvdJRwe2m|wrC=M1qxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L428MXfGeY5kfGmxbjDBd5NigQ>?MWGwMVUh|ryPMXWyOEBpMULpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nNGT2bHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
KMH2M2TGbGZ2dmO2aX;uJGF{e2G7MmfHNE02KM7:TR?=Moq1NlQhcA>?MnHRbY5pcWKrdIOgTmFMOi:VVFHUJJNq26jbHnu[y=>MYq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236NWTBU|BMTnWwY4Tpc44hSXO|YYm=M3qZVAuPSEQvF2=MViyOEBpMVTpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nM2PtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
SUPHD1MVGeY5kfGmxbjDBd5NigQ>?M2m5PVAuPSEQvF2=NGrxVYozPCCqNUfrVlR6cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NVPxdFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2NXjB[IZVTnWwY4Tpc44hSXO|YYm=NUHKPGNQOC13IN88US=>NInafmUzPCCqNVu5eJR1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NF21UGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PMnrJSpVv[3Srb36gRZN{[Xl?M2fZdFAuPSEQvF2=NHvqfHMzPCCqNUjYcYx1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
MM.1SMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLibohrUUN3ME2xMVMh|ryPNEPTOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEW4OFExOSd-MkS1PFQyODF:L3G+
TpoR JAK2 WTMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG0b4tQUUN3ME2xMlQhMDFwM,MAl|EvPSlizszNNVLyRmtHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR JAK2 V617FMl:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFWzfoFKSzVyPUCuPEApOC554pETNE46MSEQvF2=NWCbWFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR W515LNVXmN|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln0TWM2OD1yLkigLFAvP+LCk{GuNEkh|ryPMVy8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
Bcr-ablNEPtdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD1{LkegLFIvOuLCk{OuN{kh|ryPNYDUTJFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
JAK2 TWNWPFfVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MliyTWM2OD1zLkigLFEvPeLCk{KuN{kh|ryPNGHu[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEK1NVc6OCd-MkSyOVE4QTB:L3G+
JAK2 V617FMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTBwNjCoNE436oDVMD63LUDPxE1?MWq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
MedB-1NUjlS4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P5Z|Qh|ryPM33POVI1NzR6L{eyJIg>NIPc|NFVVORMXrpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5M1fXV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|OEWyN|Y3Lz5{M{i1NlM3PjxxYU6=
K1106NILEVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUe0JO69VQ>?MWCyOE81QC95MjDoNYeyV2JvTE2VTx?=NYrMOFFCcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?MX28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MkO2Okc,OjN6NUKzOlY9N2F-
U2940MoxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXW0JO69VQ>?MkXGNlQwPDhxN{KgbC=>NWT5WGk5TE2VTx?=MUDpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5NIHHTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{i1NlM3Pid-MkO4OVI{PjZ:L3G+
FE-PDMmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HJdlAvODZ|LUSg{txOM3;4OmlEPTB;OT61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NGnxe4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
HELMkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPjNE4xPjNvNDFOwG0>NXm0TWtwUUN3ME2xMlUh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5MWS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
K-562NXHOcWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrvcXp7OC5yNkOtOEDPxE1?M2HidGlEPTB;Mj61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NXW1cnZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
L-82 M3znfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vYZlAvODZ|LUSg{txOM4Ha[GlEPTB;MD65PEDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
MAC-1MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nFOlAvODZ|LUSg{txOMYrJR|UxRTBwNUKg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NWPEVW9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
MAC-2AM330VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mom3NE4xPjNvNDFOwG0>NGHJeolKSzVyPUCuOlkh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
MAC-2BNITWTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PZZlAvODZ|LUSg{txOMXjJR|UxRTBwNUSg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7M1zqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|M{eyOlY6Lz5{M{O3NlY3QTxxYU6=
MY-LAM{fnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zhS|AvODZ|LUSg{txOM2XGR2lEPTB;Mj6xJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
NC-NCMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HTR|AvODZ|LUSg{txOMYjJR|UxRTFwMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4UhGWyZX7k[Y51dHl?NFvJc4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
SE-AXMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Pke|AvODZ|LUSg{txOMmPsTWM2OD1zLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NYjLVllmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
SR-786NIf6cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fO[VAvODZ|LUSg{txONIjicpBKSzVyPUSuOkDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
M-MOKM1yyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7YT2UzPSEEtV5CpC=>MoTnNlQwPDhxN{KgbC=>NELweJNFVVORNYPJepk4cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?NVjBR21zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OVMyPTdpPkKxPFU{OTV5PD;hQi=>
HELNX3ad3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;Bd2x5UUN3ME2zNFUhdk1?MW[8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7NEW1OEc,OTh|OUS1OVQ9N2F-
Ba/F3 JAK2V617FM2fmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJ5MDDuUS=>M13BZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzF6M{m0OVU1Lz5zOEO5OFU2PDxxYU6=
MV4-11MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?MlnEO|IhcHK|M1rvXWFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtZox2SCjc4PhfUwhTUN3MDC9JFAvODd7IN88UU4>NICxTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MM1SNV;4cFZZSW62aYDyc4xqmW{YYTpeoUh[XO|YYm=NULKRXVrPzJiaILzM{TzbmFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV2xV{BkWyuczDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDJR|UxKD1iMTFOwG0vMXq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
NB1643NXvWNIVneUiWUzDhd5NigQ>?MlP2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5IhHK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{BkWyucx?=M3TJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MCNGmXXRyUFSVIHHzd4F6NIPFXnByUFSVIH;mJJBmGmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBtSCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>MVO8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
MethodsTest IndexPMID
Western blot
p-JAK2 / p-STAT1 / p-STAT3 / p-STAT6 / p-STAT5 / JAK2 ;

PubMed: 24610827

Western analysis of pJAK2 and the downstream pSTATs following treatment with vehicle or the indicated concentrations of fedratinib for 24 hours. Total JAK2 and GAPDH are similarly analyzed.

c-Myc / PIM1 ;

PubMed: 24610827

Western analysis of c-MYC and PIM1 protein levels in cHL and MLBCL cell lines treated with vehicle or fedratinib at the indicated concentration for 24 hours. Data are representative of three independent experiments.

24610827
Growth inhibition assay
Cell proliferation ;

PubMed: 24610827

Cellular proliferation of cHL cell lines (L428, KMH2, L1236, SUPHD1 and HDLM2) and the MLBCL cell line (K1106P), following treatment with vehicle or fedratinib at indicated concentration for 48 hours. For each cell line, the previously reported 9p24.1/JAK2 copy numbers (7) are indicated in parenthesis. At a given dose of the JAK2 inhibitor (1.25 μM), a Kruskal-Wallis test was performed to assess the association between the ranked values of inhibition and copy number gain (p = .009, cHL and MLBCL cell lines; p = .019, cHL cell lines).

24610827
In vivo

TG101348 has potential for efficacious treatment of JAK2V617F-associated myeloproliferative diseases (MPD). In treated animals, there is a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis, correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction. There are no apparent toxicities and no effect on T cell number. [1] Oral administration of TG101348 (120 mg/kg) significantly inhibits PV progenitor erythroid differentiation in vivo. [2]

Selleck Chemicals一直专注于生命科学领域高端试剂的开发与研究,旨在以最优价格为客户提供最优质的科研试剂服务。我们的产品包括抗体,重组蛋白,干扰rna,多肽,小分子激酶抑制剂等。Selleck Chemicals拥有一支热情与活力并存,经验与技术兼备的技术支持与客户服务团队,凭借在生命科学领域的多年研发经验,公司与多达2万多个客户建立了长期稳定的合作关系,其中包括世界各大制药厂,生物科技公司,医院及各大临床诊断实验室,世界各著名高校、研究所以及政府机关。